The short version: I'm giving JP Supplements 8 out of 10. In one day it added sources to every journal post (89 of 91 PubMed links now open the paper they name), rebuilt its lab-report wall so every card says exactly what its picture shows, and put SAHPRA's warning on the 13 product pages it applies to. But the shop still sells “research use only” vials next to a dose calculator, syringes “to draw and measure each dose”, weeks-of-supply packs and ready-to-use pens. That's why the claims check is red, the same as for Cronopharm and Peptide South Africa. And it still names no company behind the site.
What I looked at: jpsupplements.com, all 14 journal posts, all 62 product pages, the lab-reports wall and all 21 report pictures it opens, the calculator, kits, wholesale page and all 5 policies. All on 15 October 2026, after that day's fixes went live.
The score, broken down
| What I marked | Score | Why |
|---|---|---|
| Is it clear? | 2 / 2 | Plain English, “short version” boxes, tables, and a “Where the evidence stops” section on every post and product guide. |
| Is it useful? | 1 / 2 | The journal and product guides genuinely help you understand evidence levels, WADA and SAHPRA. But the shop's most-used tools serve self-injection: a calculator with typical-dose presets, syringe kits, weeks-of-supply packs and pens. Same reason Peptide South Africa got 1. |
| Are the facts right? | 2 / 2 | Every trial, label, WADA and SAHPRA figure I checked holds, and the five errors I found that morning are fixed. So are the shop-copy slips I found that afternoon (see below). |
| Does it show the evidence? | 2 / 2 | 14 of 14 posts link sources. 89 of 91 PubMed and PMC links open the paper named, and none opens an unrelated one. Posts show when sources were checked, and there's an editorial policy with a corrections address. |
| Is it honest about downsides? | 1 / 2 | Limits are stated bluntly everywhere. But safety detail is thin where the risk is highest: the GLP-1 product pages mostly leave out pancreatitis and the thyroid boxed warning, no post covers SAHPRA's warning or the 2026 GLP-1 recall, the pens carry no risk text, and the one endotoxin result isn't explained. |
| Total | 8 / 10 | Sourced writing and an honest lab wall, sold next to injection tools. |
The supplier checks
| Check | Result | Why |
|---|---|---|
| Lab reports | Amber | 34 reports JP commissioned from Janoshik, with batch, task number, dates and keys. Every card now says what its picture is, and I read all 21 pictures: each shows the report its card names. “No report held” appears on 37 product pages instead of borrowed proof. Against: one endotoxin result with no limit given, no sterility test at all, 8 pictures that are older tests than the report they link to (I couldn't open the newer ones), and 2025 batches on a shop that says it opened in May 2026. |
| Claims & dosing | Red | A dose calculator with typical doses and “units to draw”, “to draw and measure each dose” on 49 pages, weeks-of-supply packs on 13, ready-to-use pens and a Pen Starter Kit, an intranasal spray, and titration copy. Credit: no human doses in the journal, no legality claims, and SAHPRA's warning on 13 pages. |
| Basics | Amber | Email, refund, shipping and terms pages, a privacy policy that names every service it shares data with, an editorial policy, one dispatch promise everywhere, and reviews with the R100 credit disclosed. Missing: no company name, registration number, address or director anywhere, a UK WhatsApp number only, and no 7-day cooling-off line. |
What they got right
Every post now shows its sources. All 14 journal posts link their sources and say where the evidence stops. The GH post now gets the fragment right and lists the compounds banned in sport. The COA guide says the uncomfortable part: “If a report doesn't list those tests, they weren't done.” Of 91 PubMed and PMC links across the site, 89 open the paper they name. For comparison, Peptide South Africa was 25 of 41.
A lab wall that says what each report is. Every card names the report its picture shows. Where the picture is an older test than the link, it says so. Where it's JP's own summary graphic, it says that too. The one endotoxin test and the bac water preservative test are labelled as what they are, not as purity results.
SAHPRA's warning, on the products it names. All 13 product pages for the nine peptides SAHPRA lists as illegally marketed now say so, with a link to SAHPRA's notice.
It discloses the link to me. JP's editorial policy says it sells what it writes about, and that Peptide Carl is its own channel.
What dragged it down
Injection tools on a research-use shop. The calculator works out “how many units to draw” from an intended dose, with typical-dose presets for each peptide. Product pages sell syringes “to draw and measure each dose” and packs described as weeks of supply. There are pre-filled pens “ready to use once brought to room temperature”, a Pen Starter Kit asking “Prefer pen injection over syringes?”, a nasal spray bottle for compounds “handled intranasally”, and a semaglutide vial pitched past the titration phase. All of it sits under a “research use only” label. I'm not repeating the calculator's doses here. This is the same thing I marked Cronopharm and Peptide South Africa down for, so it gets the same red.
Thin on GLP-1 safety. JP's best-selling product page, tirzepatide 30 mg, lists the gut side effects but not the thyroid boxed warning on the approved medicine's label, and no GLP-1 page mentions pancreatitis. No post covers SAHPRA's warning that powder GLP-1s aren't registered, or the 2026 recall. Peptide South Africa does both.
Lab-report loose ends. The endotoxin test shows 20.1 EU per vial, above the range the lab could measure accurately, with no limit or explanation of what that means. There's no sterility test for anything. Two cards have no picture. And the home page says JP opened in May 2026, while 12 of the report pictures are 2025 batches, with no note explaining that.
Fixed before this went up. In the afternoon re-check I found five more slips, and JP fixed them before I published: a kit priced R49 in a post and R99 on its page, two sources labelled as papers they aren't, Lemon Bottle still sold as a “lipolysis solution” with syringes, glutathione pitched for “skin-tone and pigmentation”, and an SS-31 badge that didn't say which size its report was for. The saved copies (J19, J20, J21, J23, J28) show them as they were.
The basics. Nowhere on the site does JP name the company behind it, its registration number, an address or a director. The footer says “JP Research” (J26). The only phone number is a UK WhatsApp line. The refund policy doesn't mention the 7-day cooling-off right for online orders (J25). Wholesale orders “Ship from the UK” (J27). Peptide South Africa, with a 7, publishes its company name, registration number and director.
What would get them a better grade
- Turn the calculator into a concentration-only tool, drop “to draw and measure each dose” and the weeks-of-supply lines, and stop selling ready-to-use pens on a research-use shop. That alone moves claims from red.
- Publish the company name, registration number, address and directors.
- Add the GLP-1 label warnings (thyroid, pancreatitis) to those product pages, and write one post on SAHPRA's warning and the 2026 recall.
- Explain the endotoxin result against a stated limit, and commission a sterility test for the best sellers.
Do the first two and this is a 9 with a much better set of checks.
Their side
JP is our own shop, so there's no separate reply. If you think I went easy on it, tell me and I'll answer in public on this page.
Spotted something I got wrong? Tell me. I fix facts fast and say what changed. I don't change a grade because someone complains, only when I've got a fact wrong or the supplier changes what they publish.
Evidence log
| Ref | What they said | Where | Seen |
|---|---|---|---|
| J01 | “34 independent Janoshik reports.” | / · saved | 15 Oct 2026 |
| J02 | “Picture: report #70698, an earlier test. Link: report #105626.” | / · saved | 15 Oct 2026 |
| J03 | “The lab notes that results above 10 EU per vial are outside its validated range.” | / · saved | 15 Oct 2026 |
| J04 | “This tests the preservative only, not sterility.” | / · saved | 15 Oct 2026 |
| J05 | “Report #91605. Picture missing, so use the link.” | / · saved | 15 Oct 2026 |
| J06 | “Vials sold since we opened on 25 May 2026” | / · saved | 15 Oct 2026 |
| J07 | “SAHPRA lists BPC-157 among illegally marketed peptides (May 2026).” | /products/bpc-157-10mg/ · saved | 15 Oct 2026 |
| J08 | “Full-length GH is 191 amino acids long, and this fragment is the last 16 of them, positions 176 to 191.” | /2026/05/29/gh-secretagogues/ · saved | 15 Oct 2026 |
| J09 | “If a report doesn’t list those tests, they weren’t done.” | /2026/06/07/read-a-coa/ · saved | 15 Oct 2026 |
| J10 | “If Carl reviews one of our shops, the review says so at the top.” | /legal/editorial/ · saved | 15 Oct 2026 |
| J11 | “how many units to draw” | /calculator/ · saved | 15 Oct 2026 |
| J12 | Dose tool output (not repeated here) | /calculator/ · saved | 15 Oct 2026 |
| J13 | “to draw and measure each dose” | /products/wolverine-blend-10mg/ · saved | 15 Oct 2026 |
| J14 | “a complete research pack, ~5 weeks' supply.” | /products/wolverine-blend-10mg/ · saved | 15 Oct 2026 |
| J15 | “Supplied ready to use once brought to room temperature” | /products/retatrutide-pen-30mg-pre-filled/ · saved | 15 Oct 2026 |
| J16 | “Prefer pen injection over syringes?” | / · saved | 15 Oct 2026 |
| J17 | “for protocols that go past the titration phase” | /products/semaglutide-15mg/ · saved | 15 Oct 2026 |
| J18 | “For compounds handled intranasally in research protocols” | /products/nasal-spray-bottle-10ml-fine-mist-atomiser/ · saved | 15 Oct 2026 |
| J19 | “Ready-mixed lipolysis solution in a 10ml vial, from our JP Beauty line” (fixed before publication) | /products/lemon-bottle-10ml/ · saved | 15 Oct 2026 |
| J20 | “Investigated for skin-tone and pigmentation models” (fixed before publication) | /products/glutathione-1200mg/ · saved | 15 Oct 2026 |
| J21 | “The Reconstitution Kit bundles the lot for R49.” (fixed before publication) | /2026/06/04/reconstitution-storage/ · saved | 15 Oct 2026 |
| J22 | “Custom-formulated — contact us for specs and pricing” | /products/wolverine-blend-10mg/ · saved | 15 Oct 2026 |
| J23 | “No report held — ask us” (fixed before publication) | /products/ss-31-50mg/ · saved | 15 Oct 2026 |
| J24 | “The effects reported most often in the trials were gut-related” | /products/tirzepatide-30mg/ · saved | 15 Oct 2026 |
| J25 | “we are unable to accept returns or offer refunds on items that were supplied correctly” | /legal/refund/ · saved | 15 Oct 2026 |
| J26 | “© 2026 JP Research. All rights reserved.” | / · saved | 15 Oct 2026 |
| J27 | “Ships from the UK” | /wholesale/ · saved | 15 Oct 2026 |
| J28 | “Pickart: the human tripeptide GHK and tissue remodeling (review)” (fixed before publication) | /products/ghk-cu-100mg/ · saved | 15 Oct 2026 |
Update log
- 15 Oct 2026: First published. Graded after JP's same-day fixes. Morning score, before the fixes: 6/10. Five more slips found in the afternoon re-check were fixed before publishing (kit price, two source labels, Lemon Bottle and glutathione wording, SS-31 badge).
